benralizumab
Sign in to saveAlso known as BIW-8405, MEDI-563, KHK4563
Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor (CD125). It was developed by MedImmune for the treatment of asthma. It is currently marketed by Astrazeneca.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 458639521
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- zu/o
- Drug.target
- CD125
- Drug.pronounce
- ben" ra liz' ue mab
- Drug.tradename
- Fasenra
- Drug.MedlinePlus
- a618002
- Drug.DailyMedID
- Benralizumab
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- Subcutaneous
- Drug.ATC_prefix
- R03
- Drug.ATC_suffix
- DX10
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- /Schedule D
via Wikipedia infobox
Research
1,293 papers- Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.The New England journal of medicine · 2024
- Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.The Journal of allergy and clinical immunology · 2023
- Benralizumab for the Prevention of COPD Exacerbations.The New England journal of medicine · 2019
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.Lancet (London, England) · 2016
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet (London, England) · 2016
via PubMed
~1 min read
Encyclopedic overview
2 sectionsContents
- Clinical Trials
- References
Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor (CD125). It was developed by MedImmune for the treatment of asthma. It is currently marketed by Astrazeneca.
Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016. It was approved by the US Food and Drug Administration in November 2017 for the treatment of severe eosinophilic asthma. It was granted designation as an orphan drug by the Food and Drug Administration for treatment of eosinophilic oesophagitis in August 2019.
Excerpted from Wikipedia’s “benralizumab” article, available under the CC BY-SA 4.0 licence.